{
  "schemaVersion": 2,
  "eyebrow": "Endocrinology",
  "title": "Obesity and Type 2 Diabetes",
  "summary": "Excess adiposity is a central, modifiable driver of insulin resistance and type 2 diabetes progression. Management should integrate weight-directed treatment with complication-focused glucose-lowering therapy, prioritizing cardiometabolic outcomes, safety, treatment burden, and durable access.",
  "seoDescription": "Point-of-care guidance on obesity and type 2 diabetes: adiposity assessment, weight-centered pharmacotherapy, safety monitoring, and metabolic surgery.",
  "clinicalQuestion": "How should clinicians assess and treat obesity to improve glycemia and cardiometabolic outcomes in adults with type 2 diabetes?",
  "specialty": "Endocrinology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "obesity",
    "type 2 diabetes",
    "weight management",
    "GLP-1 receptor agonists",
    "tirzepatide",
    "metabolic surgery",
    "SGLT2 inhibitors"
  ],
  "keyTakeaways": [
    "Treat obesity as a chronic cardiometabolic disease in type 2 diabetes; BMI identifies risk but does not distinguish adiposity from lean mass or characterize fat distribution. Add waist-based measures or body-composition assessment when BMI is less informative. [12]",
    "For type 2 diabetes with established ASCVD, heart failure, or CKD, choose glucose-lowering therapy for cardiorenal benefit irrespective of baseline HbA1c or metformin use. GLP-1 receptor agonists and SGLT2 inhibitors address different outcome priorities. [4]",
    "Tirzepatide and subcutaneous semaglutide provide the greatest weight-loss efficacy among diabetes therapies discussed in the supplied evidence; select according to clinical indication, contraindications, tolerability, cost, and access. [4]",
    "In heart failure, use SGLT2 inhibitors for established outcome benefit; semaglutide and tirzepatide improve symptoms and function in obesity-related HFpEF, whereas evidence in HFrEF remains insufficient and earlier liraglutide studies raised safety concerns. [10][12]",
    "Weight loss should trigger proactive reassessment of insulin, insulin secretagogues, antihypertensives, and diuretics to reduce hypoglycemia, hypotension, and volume depletion. [12]"
  ],
  "sections": [
    {
      "id": "clinical-assessment",
      "eyebrow": "Assessment",
      "heading": "Assess adiposity, diabetes phenotype, and obesity-related complications",
      "intro": "Move beyond a BMI-only assessment when it changes risk classification or treatment selection.",
      "paragraphs": [
        "BMI remains a practical screening metric: U.S. obesity is conventionally BMI at least 30 kg/m², with class 1, 2, and 3 thresholds of 30 to less than 35, 35 to less than 40, and at least 40 kg/m², respectively. BMI is limited because it cannot distinguish fat from lean mass or fluid retention, and it does not characterize central adiposity. [12]",
        "Measure waist circumference in addition to BMI when central adiposity or cardiometabolic risk classification is clinically uncertain. Thresholds cited by ACC are at least 35 inches in women and at least 40 inches in men; waist-to-height ratio of at least 0.50 is also abnormal. For many Asian populations, lower BMI and waist thresholds apply. [12]",
        "The initial obesity-focused diabetes evaluation should identify treatment-relevant complications and contributors: ASCVD, HF phenotype, CKD and albuminuria, hypertension, dyslipidemia, sleep-disordered breathing, atrial fibrillation, MASLD, osteoarthritis, medication-associated weight gain, depression or eating disorder, food insecurity, and affordability barriers. Obesity and diabetes management should not be separated from prevention and treatment of these complications. [4][10][12]"
      ],
      "bullets": [
        "Document baseline weight, BMI, waist measure when useful, blood pressure, glycemic status, kidney function, lipid profile, current diabetes regimen, and weight-promoting medications. [4][12]",
        "For diabetes treatment selection, determine whether the patient has ASCVD/high ASCVD risk, HF, CKD, marked hyperglycemia, or a primary goal of weight loss. [4]",
        "Use person-first, nonstigmatizing language and shared decision-making; stigma may interfere with engagement and care delivery. [10][12]"
      ],
      "subsections": [],
      "table": {
        "caption": "Adiposity measures that can alter clinical interpretation. [12]",
        "columns": [
          "Measure",
          "Actionable interpretation",
          "Key limitation"
        ],
        "rows": [
          [
            "BMI",
            "Use for routine classification and medication eligibility; obesity is BMI ≥30 kg/m² in Europoid populations. [12]",
            "Does not distinguish adiposity from muscle or fluid and does not quantify fat distribution. [12]"
          ],
          [
            "Waist circumference",
            "Supports identification of central adiposity; abnormal at ≥35 inches in women or ≥40 inches in men in the cited U.S. thresholds. [12]",
            "Can be distorted by fluid retention, particularly in HF. [10]"
          ],
          [
            "Waist-to-height ratio",
            "A ratio ≥0.50 identifies abnormal central adiposity. [12]",
            "Thresholds and implementation are less embedded in U.S. coverage and treatment pathways than BMI. [12]"
          ],
          [
            "DXA or other body-composition assessment",
            "Consider when BMI is discordant with suspected excess adiposity, sarcopenia, or fluid-related weight change. [10][12]",
            "Access, cost, and standardization limit routine use. [10]"
          ]
        ]
      }
    },
    {
      "id": "why-weight-matters",
      "eyebrow": "Clinical consequence",
      "heading": "Link adiposity treatment to diabetes and cardiovascular risk",
      "intro": "The target is not weight alone; it is improvement in metabolic dysfunction and clinical outcomes.",
      "paragraphs": [
        "Excess and dysfunctional adipose tissue promotes insulin resistance through ectopic lipid accumulation, altered adipokine signaling, inflammation, and impaired insulin action in liver and skeletal muscle; the practical consequence is progressive hyperglycemia and greater cardiometabolic risk. [23]",
        "Weight loss as small as 5% is associated with improvement in blood pressure, triglycerides, fasting glucose, and incident diabetes risk; for people seeking improvement in weight-related comorbidities, ACC guidance identifies a practical target of at least 10% weight loss. [12]",
        "In adults with type 2 diabetes, lifestyle intervention is foundational but should not be expected to replace evidence-based pharmacotherapy when cardiorenal risk, significant obesity, or treatment failure is present. In Look AHEAD, intensive lifestyle treatment did not reduce the primary cardiovascular composite outcome versus usual care, although participants achieving at least 10% loss in year 1 had lower cardiovascular event risk in post hoc analysis. [4]"
      ],
      "bullets": [
        "Favor glucose-lowering therapies with weight loss or weight-neutral effects when clinically feasible; GLP-1 receptor agonists and SGLT2 inhibitors reduce weight, whereas insulin, sulfonylureas, and thiazolidinediones promote weight gain. [4]",
        "Consider replacing nonessential weight-promoting drugs when a clinically appropriate alternative exists. [4][21]",
        "Prescribe aerobic and resistance activity for function, glycemia, and preservation of lean mass; exercise alone generally produces less weight loss than caloric restriction but improves functional status and supports maintenance. [10][21]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "medication-selection",
      "eyebrow": "Pharmacotherapy",
      "heading": "Select diabetes therapy by cardiorenal risk and weight objective",
      "intro": "Do not use a glucose-centric sequence when comorbidities determine outcome benefit.",
      "paragraphs": [
        "For adults with type 2 diabetes and established ASCVD or indicators of high ASCVD risk, initiate a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit regardless of HbA1c or background therapy. In cardiovascular outcomes trials, dulaglutide, liraglutide, subcutaneous semaglutide, canagliflozin, and empagliflozin reduced major adverse cardiovascular events versus placebo. [4]",
        "For HF, SGLT2 inhibitors have consistent outcome benefit and should be prioritized. For CKD with eGFR below 60 mL/min/1.73 m² or albuminuria, SGLT2 inhibitors are preferred to slow CKD progression; current prescribing information described in the evidence allows initiation for kidney benefit at eGFR at least 20 mL/min/1.73 m², although glucose-lowering efficacy is substantially reduced below eGFR 45 mL/min/1.73 m². [4]",
        "When obesity or weight-related complications are a major treatment target, tirzepatide and subcutaneous semaglutide have the highest weight-loss efficacy among the glucose-lowering options summarized in the supplied evidence. Metformin and DPP-4 inhibitors are generally weight neutral; SGLT2 inhibitors produce more modest weight loss. [4]"
      ],
      "bullets": [
        "Metformin remains useful for glycemic efficacy, low hypoglycemia risk, and cost, but current evidence does not support requiring metformin before a GLP-1 receptor agonist or SGLT2 inhibitor when cardiorenal indications are present. [4]",
        "Consider insulin for symptomatic or severe hyperglycemia, ketosis, catabolic weight loss, or HbA1c above 10%; once glucotoxicity improves, reassess whether insulin intensity can be reduced. [4]",
        "Before adding basal insulin in most patients, consider a GLP-1 receptor agonist because of similar glucose-lowering efficacy with less hypoglycemia and favorable weight effects. [4]"
      ],
      "subsections": [
        {
          "heading": "Weight-directed incretin therapy",
          "paragraphs": [
            "For chronic weight management, FDA-approved obesity formulations include liraglutide 3 mg daily, semaglutide 1.7 or 2.4 mg weekly, and tirzepatide 5, 10, or 15 mg weekly in eligible adults with obesity or overweight plus a weight-related comorbidity. In cited trials, mean weight loss was 8.0% with liraglutide, 14.9% with semaglutide, and up to 20.9% with tirzepatide at maximum dose. [12]",
            "Dose escalation is designed to reduce gastrointestinal intolerance. Semaglutide starts at 0.25 mg subcutaneously weekly and is increased every 4 weeks to 1.7 or 2.4 mg. Tirzepatide starts at 2.5 mg subcutaneously weekly and is increased every 4 weeks to a maintenance dose of 5, 10, or 15 mg. [12]"
          ],
          "bullets": [
            "Avoid GLP-1–based therapies in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; hypersensitivity is also a contraindication. [12]",
            "Use caution with prior pancreatitis, gallbladder disease, diabetic retinopathy, insulin-treated diabetes, and volume-sensitive CKD or HF. [4][10][12]",
            "Expect nausea, vomiting, diarrhea, constipation, and reduced appetite; reduce to a previously tolerated dose if adverse effects persist. [12]",
            "Do not use compounded incretin products when FDA-approved products are available; ACC discourages compounded products because of dosing errors, counterfeit products, and impurity concerns. [12]"
          ]
        }
      ],
      "table": {
        "caption": "Medication selection for type 2 diabetes with obesity. [4][12]",
        "columns": [
          "Clinical priority",
          "Preferred treatment direction",
          "Important implementation point"
        ],
        "rows": [
          [
            "Established ASCVD or high ASCVD risk",
            "GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit. [4]",
            "Use independent of HbA1c or metformin exposure when indicated. [4]"
          ],
          [
            "Heart failure",
            "SGLT2 inhibitor with demonstrated HF benefit. [4]",
            "Monitor volume status and consider diuretic adjustment, especially during intercurrent illness or gastrointestinal adverse effects. [4][12]"
          ],
          [
            "CKD or albuminuria",
            "SGLT2 inhibitor preferred; GLP-1 receptor agonist is a reasonable alternative when SGLT2 inhibitor cannot be used. [4]",
            "Initiation for kidney benefit is described at eGFR ≥20 mL/min/1.73 m²; glycemic efficacy declines below eGFR 45 mL/min/1.73 m². [4]"
          ],
          [
            "Primary weight-loss objective",
            "Tirzepatide or subcutaneous semaglutide generally provide greatest weight loss. [4][12]",
            "Use obesity-indicated formulations and titration schedules when treating obesity. [12]"
          ],
          [
            "Marked symptomatic hyperglycemia or catabolism",
            "Insulin, with or without GLP-1 receptor agonist. [4]",
            "Reassess for deintensification after control improves to avoid excess weight gain and hypoglycemia. [4]"
          ]
        ]
      }
    },
    {
      "id": "safety-monitoring",
      "eyebrow": "Monitoring",
      "heading": "Monitor for hypoglycemia, volume depletion, and treatment-specific adverse effects",
      "intro": "The highest-yield safety action is active medication deintensification during weight loss.",
      "paragraphs": [
        "When initiating incretin-based weight therapy in diabetes, reassess insulin and insulin secretagogues to prevent hypoglycemia. In patients with HF or hypertension, reassess diuretics and antihypertensives during dose escalation and clinically meaningful weight loss to avoid intravascular depletion or hypotension. [10][12]",
        "SGLT2 inhibitors are associated with diabetic ketoacidosis, including euglycemic presentations. In type 2 diabetes, discontinue the SGLT2 inhibitor when ketoacidosis is suspected and hold it 3 to 4 days before scheduled surgery, during prolonged fasting or very low carbohydrate intake, and during critical illness. [4]",
        "Monitor symptoms rather than serial lipase concentrations for pancreatitis. If pancreatitis develops while receiving a GLP-1 receptor agonist, DPP-4 inhibitor, or tirzepatide, discontinue therapy and do not restart it. [4]"
      ],
      "bullets": [
        "At initiation and each titration contact: weight, glycemic data, gastrointestinal tolerance, hydration, blood pressure, hypoglycemia, and adherence/access. [12]",
        "In patients with HF, CKD, diuretic use, or significant gastrointestinal symptoms: recheck kidney function and electrolytes as clinically indicated during early incretin dose escalation. [10]",
        "With semaglutide in pre-existing diabetic retinopathy, arrange close retinal surveillance; rapid HbA1c reduction may contribute to early worsening. [4]",
        "Monitor for gallbladder symptoms; GLP-1–based therapies are associated with increased gallbladder and biliary disease risk. [4][12]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "heart-failure-and-procedures",
      "eyebrow": "Advanced treatment",
      "heading": "Use phenotype-specific evidence for heart failure and metabolic procedures",
      "intro": "Intentional weight loss is clinically useful, but the evidence base differs substantially by HF phenotype and intervention.",
      "paragraphs": [
        "In obesity-related HFpEF, semaglutide and tirzepatide have randomized evidence for improved symptoms and functional capacity. In STEP-HFpEF, semaglutide improved Kansas City Cardiomyopathy Questionnaire clinical summary score and 6-minute walk distance; in SUMMIT, tirzepatide reduced the composite of cardiovascular death or worsening HF. [10][12]",
        "Do not extrapolate HFpEF incretin evidence to HFrEF. Earlier liraglutide trials in advanced HFrEF raised concern for HF hospitalization and arrhythmias, while larger cardiovascular outcomes studies have not demonstrated clear harm; safety and efficacy of modern anti-obesity incretin therapy in HFrEF remain uncertain. [10]",
        "Metabolic and bariatric surgery produces larger and more durable weight loss than lifestyle therapy or pharmacotherapy, but established HF increases perioperative risk. Observational data suggest fewer HF events after surgery, yet randomized outcomes trials in established HF are lacking; optimize HF therapy and refer to experienced multidisciplinary centers. [10]"
      ],
      "bullets": [
        "For metabolic surgery, the cited ASMBS/IFSO indications include BMI at least 35 kg/m², or BMI 30 to 34.9 kg/m² with metabolic disease. [10]",
        "In HF, stabilize volume status and guideline-directed therapy before procedural referral; postoperative risks include MI, pulmonary edema, atrial fibrillation, AKI, respiratory failure, and sepsis. [10]",
        "Protect lean mass during pharmacologic or procedural weight loss with nutritional and resistance-training strategies, particularly in older adults or patients with frailty. [10][12]"
      ],
      "subsections": [],
      "table": null
    }
  ],
  "faq": [
    {
      "question": "Should metformin be required before starting a GLP-1 receptor agonist or SGLT2 inhibitor?",
      "answer": "No when cardiorenal indications drive treatment. GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated benefit may be initiated for ASCVD, HF, or CKD independent of HbA1c and background metformin use. [4]"
    },
    {
      "question": "Which diabetes medications are most useful when obesity is the dominant treatment target?",
      "answer": "Tirzepatide and subcutaneous semaglutide provide the greatest weight-loss efficacy in the supplied evidence. SGLT2 inhibitors provide more modest loss but may be preferred for HF or CKD outcome benefit. [4][12]"
    },
    {
      "question": "When should an SGLT2 inhibitor be held?",
      "answer": "Hold SGLT2 inhibitors 3 to 4 days before scheduled surgery and during prolonged fasting, very low carbohydrate intake, or critical illness because of ketoacidosis risk; discontinue promptly if ketoacidosis is suspected. [4]"
    },
    {
      "question": "Are GLP-1-based therapies appropriate in HFrEF?",
      "answer": "Evidence is insufficient. HFpEF data support symptom and functional benefit, but earlier liraglutide studies in advanced HFrEF raised safety concerns; use individualized specialist-informed decision-making. [10]"
    },
    {
      "question": "What weight-loss target should be discussed with a patient with type 2 diabetes?",
      "answer": "An initial target of at least 5% is associated with improvement in glycemic and cardiometabolic measures; at least 10% is a practical target when attempting to improve weight-related comorbidities. [12]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "WHO Guideline on GLP-1 Therapies for Obesity in Adults",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2842199",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 2,
      "title": "Utility of current obesity thresholds in signaling diabetes ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/3/1/e000114",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com"
    },
    {
      "number": 3,
      "title": "Type 2 diabetes in adults - History and exam",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/24/history-exam",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 4,
      "title": "Advances in the management of type 2 diabetes in adults",
      "detail": "bmjmedicine.bmj.com",
      "url": "https://bmjmedicine.bmj.com/content/2/1/e000372",
      "authors": "bmjmedicine.bmj.com",
      "host": "bmjmedicine.bmj.com"
    },
    {
      "number": 5,
      "title": "Type 2 diabetes in adults - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/24",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 6,
      "title": "Obesity in children - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/1085?locale=zh_CN",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 7,
      "title": "Association of body indices and risk of mortality in patients ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/11/4/e003474",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com"
    },
    {
      "number": 8,
      "title": "Lifetime risk to progress from pre-diabetes to type 2 ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/8/2/e001529",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com"
    },
    {
      "number": 9,
      "title": "Obesity Management in Adults: A Review | Bariatric Surgery",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/article-abstract/2812316",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 10,
      "title": "2025 ACC Scientific Statement on the Management of ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2025.05.008",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 11,
      "title": "Long-Term Impact of Clinical Obesity on Heart Failure Development and Prognosis: New Insights",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacasi.2026.01.031",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 12,
      "title": "2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 13,
      "title": "important role of comorbidities in the management of obesity",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/10/3/bvag012/8430946",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 14,
      "title": "Screening for Type 2 Diabetes and Dysglycemia",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/epirev/article/33/1/63/483202",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 15,
      "title": "Risk Factors for Progression to Type 2 Diabetes in a Pediatric ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/7/11/bvad118/7300968",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 16,
      "title": "Body Mass Index and Diabetes Incidence Across the Adult ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/8/11/bvae156/7749601",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 17,
      "title": "Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2667368125000166",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 18,
      "title": "Obesity Management - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/obesity-management",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 19,
      "title": "Obesity Management - an overview | ScienceDirect Topics",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/nursing-and-health-professions/obesity-management",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 20,
      "title": "Surgical and interventional approaches for the treatment of ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1933287425005069",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 21,
      "title": "Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10342979",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Executive Summary - Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK2008",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "The Role of Obesity in Type 2 Diabetes Mellitus—An Overview",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10855901",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Treatment of Obesity in Patients With Diabetes - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5687113",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "WHO Guideline on GLP-1 Therapies for Obesity in Adults",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2842199",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "by F Celletti · 2026 · Cited by 145 — WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits. Both recommendations were",
      "score": 0.062749125
    },
    {
      "number": 2,
      "title": "Utility of current obesity thresholds in signaling diabetes ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/3/1/e000114",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com",
      "snippet": "by P Manjoo · 2015 · Cited by 14 — Being at or above the WHO obesity body mass index threshold of 30 kg/m2 or more signals elevated insulin resistance in Cree women and men. Being at or above the ...Read more",
      "score": 0.53123426
    },
    {
      "number": 3,
      "title": "Type 2 diabetes in adults - History and exam",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/24/history-exam",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Key risk factors include older age; overweight/obesity; It is very common for type 2 diabetes to be asymptomatic, clinicians should have a low threshold for",
      "score": 0.42849702
    },
    {
      "number": 4,
      "title": "Advances in the management of type 2 diabetes in adults",
      "detail": "bmjmedicine.bmj.com",
      "url": "https://bmjmedicine.bmj.com/content/2/1/e000372",
      "authors": "bmjmedicine.bmj.com",
      "host": "bmjmedicine.bmj.com",
      "snippet": "## Weight management in type 2 diabetes\n\nAmong adults with diabetes in the US, almost 28% are overweight (body mass index 25.0-29.9), 46% have obesity (body mass index 30.0-39.9), and 16% have severe obesity (body mass index ≥40.0).136 Increasingly recognised as a chronic disease, obesity (termed ad",
      "score": 0.3864398
    },
    {
      "number": 5,
      "title": "Type 2 diabetes in adults - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/24",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Comorbidities commonly associated with type 2 diabetes include obesity, hypertension, heart failure, and sleep disorders, as well as other conditions associated with macrovascular complications (coronary artery, cerebrovascular, and peripheral vascular disease) and microvascular complications (nephr",
      "score": 0.33541664
    },
    {
      "number": 6,
      "title": "Obesity in children - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/1085?locale=zh_CN",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Calculating body mass index (BMI) is the most widely accepted method of screening for obesity in children. Abnormal BMI cutoffs in children are determined by age- and sex-specific percentiles.\n\nImpaired glucose tolerance and type 2 diabetes mellitus are prevalent in children with obesity.\n\nPreventin",
      "score": 0.277219
    },
    {
      "number": 7,
      "title": "Association of body indices and risk of mortality in patients ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/11/4/e003474",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com",
      "snippet": "by CI Li · 2023 · Cited by 23 — Our study showed that ABSI alone is useful in discriminating all-cause and CVD mortality risks in patients with T2D. ABSI combined with BMI as a ...Read more",
      "score": 0.24694668
    },
    {
      "number": 8,
      "title": "Lifetime risk to progress from pre-diabetes to type 2 ...",
      "detail": "drc.bmj.com",
      "url": "https://drc.bmj.com/content/8/2/e001529",
      "authors": "drc.bmj.com",
      "host": "drc.bmj.com",
      "snippet": "by TTW van Herpt · 2020 · Cited by 83 — At age 45 years, the remaining lifetime risk to progress to overt diabetes was 57.5% (95% CI 51.8% to 63.2%) vs 80.2% (95% CI 74.1% to 86.3%) in",
      "score": 0.1513414
    },
    {
      "number": 9,
      "title": "Obesity Management in Adults: A Review | Bariatric Surgery",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/article-abstract/2812316",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "by A Elmaleh-Sachs · 2023 · Cited by 891 — Comprehensive, evidence-based obesity treatment combines behavioral interventions, nutrition, physical activity, pharmacotherapy, and metabolic/",
      "score": 0.23009738
    },
    {
      "number": 10,
      "title": "2025 ACC Scientific Statement on the Management of ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2025.05.008",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "Risk assessment and evaluation of obesity and HF\nBecause individuals with obesity have lower natriuretic peptide concentrations, lower thresholds are used in those who have obesity and exertional dyspnea to avoid underdiagnosis of HF in this population, although specific thresholds are not currently",
      "score": 0.5155961
    },
    {
      "number": 11,
      "title": "Long-Term Impact of Clinical Obesity on Heart Failure Development and Prognosis: New Insights",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacasi.2026.01.031",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "To overcome the limitations and shortcomings of traditional obesity diagnosis and achieve more accurate assessments, _The Lancet Diabetes & Endocrinology_ Commission has proposed the “Definition and Diagnostic Criteria for Clinical Obesity.”9 This new standard not only requires at least 2 anthropome",
      "score": 0.38262632
    },
    {
      "number": 12,
      "title": "2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "### 2.2 Diagnosis\n\nOverweight and obesity are defined as “abnormal or excessive fat accumulation that presents a risk to health.”10,11 Obesity is often diagnosed using BMI, which is calculated using an individual’s weight and height. As classified by the Centers for Disease Control and Prevention, w",
      "score": 0.30812827
    },
    {
      "number": 13,
      "title": "important role of comorbidities in the management of obesity",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/10/3/bvag012/8430946",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by SR Barenbaum · 2026 · Cited by 3 — WHR of <0.5 is normal, while 0.5-0.59 indicates elevated health risk, and ≥0.6 indicates high health risk. WHR should be measured in",
      "score": 0.19365044
    },
    {
      "number": 14,
      "title": "Screening for Type 2 Diabetes and Dysglycemia",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/epirev/article/33/1/63/483202",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by JB Echouffo-Tcheugui · 2011 · Cited by 112 — A recent expert panel recommended a random blood glucose cutoff of ≥7.2 mmol/L, which has a sensitivity of 63% and specificity of 87%, based on validation",
      "score": 0.17990519
    },
    {
      "number": 15,
      "title": "Risk Factors for Progression to Type 2 Diabetes in a Pediatric ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/7/11/bvad118/7300968",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by N Belsky · 2023 · Cited by 15 — In our cohort, patients who progressed to T2D had a higher BMI at baseline and saw continued gains with an average increase of 4.2 kg/m2 from ...Read more",
      "score": 0.17762567
    },
    {
      "number": 16,
      "title": "Body Mass Index and Diabetes Incidence Across the Adult ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jes/article/8/11/bvae156/7749601",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by N Malandrino · 2024 · Cited by 7 — WHO-defined BMI categories for overweight and obesity were generally related to higher diabetes risk compared to normal weight in all ages except 50 to 59 years ...Read more",
      "score": 0.16856964
    },
    {
      "number": 17,
      "title": "Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2667368125000166",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "2026, Obesity Medicine  Show abstract Obesity, type 2 diabetes mellitus (T2DM) and hypertension are interrelated cardiometabolic disorders that collectively drive the global burden of cardiovascular disease (CVD), chronic kidney disease (CKD) and premature mortality. Traditional therapeutic approach",
      "score": 0.35555163
    },
    {
      "number": 18,
      "title": "Obesity Management - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/obesity-management",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "While bariatric surgery remains the most effective treatment for obesity, it appears that interventional therapy by endoscopy, as well as personalized drug",
      "score": 0.32578912
    },
    {
      "number": 19,
      "title": "Obesity Management - an overview | ScienceDirect Topics",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/nursing-and-health-professions/obesity-management",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "The management of obesity includes conservative therapies (i.e., lifestyle changes and behavioral modification), medical therapies, and surgery.",
      "score": 0.26729923
    },
    {
      "number": 20,
      "title": "Surgical and interventional approaches for the treatment of ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1933287425005069",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by L Gant · 2026 · Cited by 2 — The interventional approaches for the treatment of obesity currently include bariatric surgery procedures and intragastric and endoscopic procedures.",
      "score": 0.23580319
    },
    {
      "number": 21,
      "title": "Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10342979",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "The ADA recommends an overall energy deficit of 500–750 kcal/day. This roughly translates into a daily caloric content in the diet equal to 1200–1500 kcal/day for women and 1500–1800 kcal/day for men. “Joslin Clinical Nutrition Guideline for Overweight and Obese Adults With Type 2 Diabetes (T2D) or ",
      "score": 0.78294516
    },
    {
      "number": 22,
      "title": "Executive Summary - Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK2008",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "To evaluate published information and to determine the most appropriate treatment strategies that would constitute evidence-based clinical guidelines on overweight and obesity for physicians and associated health professionals in clinical practice, health care policy makers, and clinical investigato",
      "score": 0.70750624
    },
    {
      "number": 23,
      "title": "The Role of Obesity in Type 2 Diabetes Mellitus—An Overview",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10855901",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "## . Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—The evidence report. _Obes. Res._. 1998. 6((Suppl. S2)):51S-209S.  [PubMed] [Google Scholar&publication_year=1998&pages=51S-209S&pmid=9813653&)]\n   3..Kelly T., Yang W., Chen C.S., Reynolds ",
      "score": 0.68571854
    },
    {
      "number": 24,
      "title": "Treatment of Obesity in Patients With Diabetes - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5687113",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "When patients are ready to discuss weight loss strategies, clinicians should determine whether they are able to provide intensive counseling and follow-up for weight loss in their clinical practice or whether they should instead refer patients to an outside weight loss program. The 2016 ADA guidelin",
      "score": 0.6638657
    }
  ],
  "publishedAt": "2026-08-21T00:04:47.745086Z",
  "updatedAt": "2026-08-21T00:04:47.745086Z",
  "readingMinutes": 7,
  "slug": "obesity-and-type-2-diabetes"
}